Stockscreener 앱 받기
87.72
0.64%
-0.97
시간 외 거래:
87.72
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating - 富途牛牛
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $158 - Moomoo
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After A Recent Share Price Pullback - Sahm
Is Rhythm Pharmaceuticals (RYTM) Still Attractive After A 48.9% One‑Year Share Price Gain - Sahm
Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Hold - MarketBeat
Risk Analysis: Is Rhythm Pharmaceuticals Inc gaining market share2026 Outlook & Reliable Price Action Trade Plans - baoquankhu1.vn
RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - The Manila Times
Should I trade or invest in Rhythm Pharmaceuticals Inc2026 Fundamental Recap & Real-Time Buy Signal Alerts - baoquankhu1.vn
Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next - Sahm
Dip Buying: Is Rhythm Pharmaceuticals Inc currently under institutional pressureGap Down & Weekly Breakout Stock Alerts - baoquankhu1.vn
Momentum Shift: What are Rhythm Pharmaceuticals Incs growth leversWeekly Trade Analysis & Weekly Setup with High ROI Potential - baoquankhu1.vn
RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $136 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach - Sahm
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance
Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information - Minichart
Rhythm Pharmaceuticals Announces Changes to Board of Directors - Sahm
Rhythm Pharmaceuticals adds Kim Popovits to board of directors By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
RHYTHM (RYTM) director receives 6,808 RSUs and 10,257 stock options - Stock Titan
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan
Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan
Rhythm Pharmaceuticals, Inc. Announces Changes in Board of Directors - MarketScreener
Rhythm Pharmaceuticals adds Kim Popovits to board of directors - Investing.com
Rhythm Pharmaceuticals Appoints Kim Popovits to Board - citybiz
Rhythm Pharmaceuticals Announces Appointment of Kim Popovits as Director and Departure of Ed Mathers - Quiver Quantitative
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Strength seen in Rhythm Pharmaceuticals (RYTM): Can its 12.6% jump turn into more strength? - MSN
Rhythm posts first FDA approval for acquired hypothalamic obesity - Longevity.Technology
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? - qz.com
Rhythm Pharma higher after FDA label expansion for lead drug - MSN
Rhythm Pharmaceuticals: Imcivree FDA Approval & Market Growth in 2025News and Statistics - IndexBox
Rhythm Pharma wins EU backing to expand Imcivree label - MSN
Discipline and Rules-Based Execution in RYTM Response - Stock Traders Daily
1.62%
1.49%
자본화:
|
볼륨(24시간):